Cardio DiagnosticsCDIO
About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Employees: 9
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0% more funds holding
Funds holding: 23 [Q4 2024] → 23 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.49% less ownership
Funds ownership: 6.36% [Q4 2024] → 4.86% (-1.49%) [Q1 2025]
65% less capital invested
Capital invested by funds: $2.36M [Q4 2024] → $836K (-$1.52M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for CDIO.
Financial journalist opinion
Based on 3 articles about CDIO published over the past 30 days









